Molinalogo

Measure

2021

2022

Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

72.98%

64.13%

64.52%

Annual Dental Visits (ADV) Total

NB

NB

53.67%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

36.07%

32.40%

46.09%

Appropriate Testing for Pharyngitis (CWP)

82.47%

71.59%

74.02%

Appropriate Treatment for Upper Respiratory Infection (URI)

85.39%

88.16%

92.46%

Asthma Medication Ratio (AMR) Total

64.50%

63.15%

68.21%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB)

47.72%

50.11%

58.74%

Breast Cancer Screening (BCS)

57.64%

53.25%

53.96%

Cervical Cancer Screening (CCS)

58.15%

62.53%

60.83%

Childhood Immunization Status (CIS) Combination #10

32.12%

25.79%

39.42%

Chlamydia Screening in Women (CHL) Total

59.16%

57.78%

60.24%

Comprehensive Diabetes Care (CDC) BP Control <140/90

60.34%

64.72%

65.21%

Comprehensive Diabetes Care (CDC) HbA1c Control <8.0%

44.77%

46.23%

52.80%

Comprehensive Diabetes Care (CDC) Eye Exam

55.96%

56.45%

54.74%

Controlling High Blood Pressure (CBP)

47.45%

54.74%

63.50%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

74.31%

79.97%

81.21%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

11.59%

11.23%

16.16%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

38.55%

42.06%

45.35%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

39.70%

37.88%

42.75%

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total

28.96%

25.19%

37.86%

Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase

66.34%

45.50%

55.40%

Immunizations for Adolescents (IMA) Combination #2

32.60%

28.95%

39.16%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Rate Total

11.54%

11.92%

16.57%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Total

25.98%

26.94%

39.29%

Pharmacotherapy for Opioid Use Disorder (POD) Total

24.28%

52.43%

33.15%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

70.38%

68.87%

74.76%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

82.88%

79.47%

87.83%

Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years

92.12%

89.25%

≤ 94.44%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

92.70%

87.83%

87.83%

Prenatal and Postpartum Care (PPC) Postpartum Care

74.45%

75.67%

80.00%

Prenatal Immunization Status (PRS) Combination Rate

18.37%

13.89%

27.32%

Risk of Continued Opioid Use (COU) 31-Day Total

3.45%

2.83%

≤ 2.35%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

80.70%

82.32%

82.29%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

67.06%

59.68%

73.75%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

66.72%

66.58%

68.32%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

63.48%

55.51%

70.00%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

60.43%

54.50%

65.63%

Use of Imaging Studies for Low Back Pain (LBP)

68.74%

68.69%

76.82%

Use of Opioids at High Dosage (HDO)

2.69%

1.93%

≤ 2.65%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

2.04%

1.16%

≤ 0.90%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

73.24%

70.56%

82.73%